Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Botulinum Toxin Type A

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Botulinum Toxin and Short-Term Electrical Stimulation in the Treatment of Equinus in Cerebral Palsy; Detrembleur et al
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24425
    Study title: Botulinum Toxin in Cerebral Palsy Upper Extremity Performance: A Placebo Controlled, Double Blind Study
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24431
    Study title: Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial; Keshtgara et al
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24424
    Study title: Effect of Botulinum Toxin in the Treatment of Drooling: A Controlled Clinical Trial; Jongeriu et al,
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24423
    Study title: Evaluation by gait analysis of injection into the rectus femoris - semitendinosus muscle pair
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24418
    Study title: Injections of Botulinum Toxin A in salivary glands in persons with cerebral palsy and a drooling problem.
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24420
    Study title: Parameters for predicting favourable responses to botulinum toxin in children with cerebral palsy; Fattal-Valevski et al
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24421
    Study title: The use of botulinum toxin type A in spastic diplegia due to cerebral palsy; Ward et al
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24426
    Study title: A double-blind, prospective, randomised, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of Dysport with placebo in lower limb spasticity in children with cerebral palsy
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
    Study summary document link (including results):
    View full study record
    Document reference: 24433
    Study title: A phase IV, monocentre, open, non-comparative, prospective study to evaluate the efficacy and tolerability of Dysport in the treatment of Dynamic Equinus Foot Deformity in young children with Cerebral Palsy
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
    Study summary document link (including results):
    View full study record
    Document reference: 24436
    Study title: A randomised, double-blind, placebo-controlled study to compare the efficacy and safety of Dysport with placebo in lower limb muscle spasticity in patients with spastic cerebral palsy
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
    Study summary document link (including results):
    View full study record
    Document reference: 24434
    Study title: An assessor-blind, prospective, randomised, chronic dosing study to compare the long-term efficacy and safety of two differing Dysport dosage regimens in the treatment of lower limb spasticity in children with cerebral palsy.
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A - HAEMAGGLUTININ COMPLEX
    Study summary document link (including results):
    View full study record
    Document reference: 24435
    Study title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Increased Muscle Tone of the Lower Limb Resulting in Abnormal Gait A
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24428
    Study title: A Multicenter, Open-Label Study of the Safety and Efficacy of Repeated Treatments with BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Primary Axillary Hyperhidrosis in Adolescents
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 22689
    Study title: An Evaluator-Blinded Randomized Pilot Study Comparing the Use of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin complex to Standard Care in the Management of the Hemiplegic Upper Limb in Paediatric Cerebral Palsy. 6-Month Report.
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 24429
    Study title: Functional improvement in upper limb following BOTOX® treatment
    Active substance: CLOSTRIDIUM BOTULINUM TOXIN TYPE A
    Study summary document link (including results):
    View full study record
    Document reference: 22681
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 05:38:34 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA